Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT00640731
Other study ID # 2007-US-001
Secondary ID
Status Enrolling by invitation
Phase Phase 4
First received March 17, 2008
Last updated March 20, 2008
Start date March 2008
Est. completion date July 2008

Study information

Verified date March 2008
Source OmniSonics Medical Technologies, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This is a prospective, multi-center single arm registry to assess the use of the OmniWave Endovascular System in subjects presenting with either lower or upper extremity acute (symptoms have been present for greater than or equal to 14 days) DVT.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 50
Est. completion date July 2008
Est. primary completion date July 2008
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- DVT confirmed by venographic and ultrasound imaging, which has been symptomatic for a maximum of 14 days, or diagnosed within past 14 days defined as either first episode (no prior history in affected segment), or recurrent episode.

- Written informed consent

- Agreement to comply with follow up requirements

Exclusion Criteria:

- Known R-L shunt, pulmonary A-V malformation

- Excessive tortuosity and/or sharp angulation in target treatment zone

- Isolated calf vein thrombosis

- Isolated DVT in veins peripheral to axillary vein

- Thrombus in peripheral vessel smaller than 5 mm

- Target treatment zone cannot be adequately accessed within the 100 cm working length of device

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
OmniWave Endovascular System
Treatment with mechanical thrombolysis/thrombectomy

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
OmniSonics Medical Technologies, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Procedural success rate defined as at least 50% reduction in thrombus burden in each target treatment zone following use of the OmniWave Endovascular System Post-Index procedure No
Secondary Death, clinically detectable PE, significant vessel damage in target treatment area through 6 months post-index procedure Yes
Secondary Restoration and maintenance of antegrade in-line flow in target treatment area through 6 months post-index procedure No
Secondary QOL SF-36 through 6 months post-index procedure No
Secondary Incidence of clinically significant hemolysis Prior to discharge Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05003843 - BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis N/A
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Withdrawn NCT04136561 - Novel Strategy to Encourage Early Removal of Central Venous Catheters N/A
Completed NCT03420625 - Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Completed NCT02555111 - Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. Phase 3
Terminated NCT02469376 - Evaluation of a New Imagingtechnologie for Thrombosis Phase 1
Completed NCT01975090 - The SENTRY Clinical Study N/A
Completed NCT02037607 - Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures N/A
Not yet recruiting NCT01357941 - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) N/A
Completed NCT00771303 - Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
Completed NCT00720915 - D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months N/A
Completed NCT00773448 - Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism N/A
Completed NCT00244725 - Odiparcil For The Prevention Of Venous Thromboembolism Phase 2
Completed NCT00264277 - D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism Phase 4
Completed NCT00365950 - 3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE Phase 4
Completed NCT00182403 - Fixed Dose Heparin Study Phase 3
Completed NCT03682419 - Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL) N/A
Not yet recruiting NCT04981327 - The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis Phase 3
Recruiting NCT03240120 - A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism Phase 3